Synonyms: example 18 [WO2013166396A2]
Compound class:
Synthetic organic
Comment: The chemical structure that was submitted to the WHO for the INN ipivivint leads to Samumed's patent WO2013166396A2 , as compound 18 therein [1]. Ipivivint is defined as a Wnt pathway inhibitor. Samumed have a lead candidate called SM08502 in their pipeline. SM08502 is reported to decrease Wnt signalling in tumour cells via inhibition of CDC-like kinase (CLK) activity in an article from Samumed scientists [2]. We speculate that ipivivint might be SM08502, but as of August 2020 there is no formal disclosure of SM08502's chemical structure. SM08502 is being investigated in a Phase 1 clinical trial in patients with advanced solid tumours (NCT03355066).
|
|
Classification | |
Compound class | Synthetic organic |
International Nonproprietary Names | |
INN number | INN |
11425 | ipivivint |
Synonyms |
example 18 [WO2013166396A2] |
Database Links | |
BindingDB Ligand | 270451 |
CAS Registry No. | 1481617-15-5 (source: WHO INN record) |
GtoPdb PubChem SID | 434122247 |
PubChem CID | 136213660 |
Search Google for chemical match using the InChIKey | YBBUGSYNPXTSGW-UHFFFAOYSA-N |
Search Google for chemicals with the same backbone | YBBUGSYNPXTSGW |
Search PubMed clinical trials | ipivivint |
Search PubMed titles | ipivivint |
Search PubMed titles/abstracts | ipivivint |
UniChem Compound Search for chemical match using the InChIKey | YBBUGSYNPXTSGW-UHFFFAOYSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | YBBUGSYNPXTSGW-UHFFFAOYSA-N |